γ-Globulin |
1.7×107
|
5 |
GNN (16), ANN (15), CNN (15) |
VP64 or KRAB |
4 |
[165] |
CD58, CDH5, EGF, FUT4, ICAM1, ERBB2, ERBB3, ITGA6, ITGB4 and TNFRSF6 |
1.0×104 and 8.4×107
|
3 and 6 |
GNN (16), ANN (4), TNN (3) |
VP64 |
4 for CDH5 |
[68] |
ICAM-1 |
8.4×107
|
6 |
GNN (16), ANN (4), TNN (3) |
VP64 |
4 |
[163] |
Taxol resistance |
8.4×107
|
6 |
GNN (16), ANN (4), TNN (3) |
VP64 |
1 |
[172] |
Drug resistance |
1.0×104 and 8.4×107
|
3 and 6 |
GNN (16), ANN (4), TNN (3) |
VP64 |
3 |
[174] |
VEGF |
1.5×102
|
3 |
GNN (28), ANN (4), other (4) |
p65 or VP16 |
4 |
[60] |
Neuronal morphology, ALP |
2.4×105
|
4 |
GNN (37), ANN (9), TNN (2), other (7) |
p65 or KRAB |
2 |
[170] |
Taxol resistance |
Not described |
4 |
25 from [60] |
p65 |
2 |
[171] |
SEAP |
2.4×105
|
3 and 4 |
GNN (37), ANN (9), TNN (2), other (7) |
p65 or KRAB |
3 |
[222] |
Production of antibodies against TAG72 |
2.4×105
|
4 |
GNN (37), ANN (9), TNN (2), other (7) |
VP16 or KRAB |
4 |
[173] |
Fulvestrant resistance |
4.0×105
|
4 |
GNN (14), ANN (15), CNN (15) |
p65 |
6 |
[221] |